AZNAstraZenecaRunning, no new patients
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 108 (final count)
- Started
- Dec 13, 2023
- Main results expected
- Oct 31, 2028
- Fully finished
- Oct 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
MRD-negative CR rate
Measured over: At the end of AVR induction, i.e., following completion of Cycle 13 (each cycle is 28 days)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05951959 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC